Chemical Business Newsbase articles from November 2009, page 3

Chemical Business Newsbase archives from November 2009

Huntsman EO leak halts plant.
November 30, 2009... An ethylene oxide (EO) leak on 28 Oct 2009 at Huntsman's glycol ether facility in Botany, Australia forced Huntsman to temporarily stop production. An instrument malfunction caused the release of around 1500 lbs of EO into the air. Operations...

Solvay cuts polymers jobs.
November 30, 2009... Solvay Advanced Polymers will lay off around 50 employees, or around 8% of its workforce, in line with a restructuring initiative. Around 23 employees will be laid off at the firm's Marietta, OH, USA site, or around 10% of the site's headcount....

Dow lifts force majeure.
November 30, 2009... Dow Chemical has ended the toluene diisocyanate (TDI) force majeure at Freeport, TX, USA. The TDI force majeure was declared in mid-Oct 2009 because of broken equipment at the site.

Oswal plans caustic plant.
November 30, 2009... New Delhi, India-based Oswal Group plans to establish a $400 M caustic soda facility in Salalah, Oman. Construction is set to begin in 4Q 2010. The fertilizer and mining firm anticipates output from the plant to serve the Mideast and...

Tronox names distributor.
November 30, 2009... Tronox has appointed Dowd and Guild of San Ramon, CA, USA as distributor of titanium dioxide in western USA.

CW price report: prices as they stood in the week before 30 Nov 2009. [1 table, 4 figures in original article].
November 30, 2009... Prices as they stood in the week before 30 Nov 2009 are discussed for ethane, naphtha, propane, butane, ethylene, propylene, butadiene, benzene, toluene, mixed xylene, styrene, methyl tert-butyl ether, polyethylene, (PE), low density PE, linear...

Leading indicator: reversing course. [1 table, 1 figure in original article].
November 30, 2009... The main indicator for the chemical sector contracted 0.8% in Nov 2009, the first drop since Jul 2009. Concurrently, chemical industry output increased 0.3%, mirroring earlier gains in the indicator. Chemicals production has increased for five...

Focus on propylene: Gulf capacity build-up reflects feedstock diversification. [1 table in original article].
November 30, 2009... Propylene capacity expansion projects in the Gulf region suggest a move towards the use of a wider range of raw materials. Major investments in propane hydrogenation, mixed-feed steam crackers and metathesis are contributing to a significant...

Combined sales of 21 JPMA member companies up 1.6%: 1H FY ending Mar 2010. [1 table in original article].
November 30, 2009... The aggregate sales for 1H FY ending Mar 2010 of 21 JPMA member firms listed in the first section of the Tokyo Stock Exchange grew 6% year on year to Yen 3117.0 bn, based on figures compiled by Jiho Inc. Combined operating profits surged 33.8%...

Blopress Japan's best-selling drug in 2Q 2009: IMS Japan.
November 30, 2009... Sales of ethical pharmaceuticals in Japan rose by 8.7% year on year to Yen 2,184,270 bn, according to sales figure based on NHI pricing for 3Q 2009 compiled by IMS Japan. Drugs that showed double-digit gains include Eisai's Aricept (donepezil)...

Otsuka HD: pharma division sales total Yen 357.5 bn: Apr-Sep 2009.
November 30, 2009... Osuka Holdings (Otsuka HD) reported sales of Yen 553,872 M in its consolidated settlement of accounts for 1H FY 2009, spurred by robust gains in sales of the antipsychotic agent Abilify (aripirazole). Operating profits reached Yen 60,324 M,...

Kaken licenses bFGF to Olympus in Europe, North America.
November 30, 2009... Kaken Pharmaceutical and Olympus Corp completed recently a licence deal for the development, production and sale of basic fibroblast growth factor (bFGF) for wound healing, in Europe and North America. Kaken currently holds the global...

Sciele Pharma to acquire Addrenex: Shionogi.
November 30, 2009... Shionogi revealed recently that its US subsidiary Sciele Pharma Inc had purchased Addrenex Pharmaceuticals Inc for $29 M, on 13 Nov 2009. Addrenex has expertise in the development of pharmaceuticals for adrenergic dysregulation. The deal will...

Eisai launches sedative-hypnotic Lusedra in the USA.
November 30, 2009... Eisai Inc introduced recently to the US market its first commercialized intravenous sedative-hypnotic agent, Lusedra (fospropofol disodium) Injection CIV. The firm anticipates sales of Lusedra to reach $100 M in FY 2012. Lusedra, when given...

Vibativ launched in the USA: Astellas.
November 30, 2009... Theravance Inc and Astellas Pharma US Inc announced recently the commercialization of their bactericidal once-a-day injectable lipoglycopeptide antibiotic Vibativ (telavancin) in the USA. Featuring a dual mechanism of action, Vibativ was cleared...

Alexion Pharma to hire up to 13 MCCs in Japan: president Strenger.
November 30, 2009... Alexion Pharma KK is kicking off full-scale business operations in Japan, according to company president Herman Strenger. The company will hire up to 13 new medical customer care (MCC) specialists by mid-2010. Alexion developed eculizumab as the...

Daiichi Sankyo wins levofloxacin patent lawsuit in the UK.
November 30, 2009... Daiichi Sankyo announced recently that it won the UK patent case involving its wide-ranging antibacterial agent levofloxacin (brand name in the UK: Tavanic; brand name in Japan: Cravit). Levofloxacin's UK patent will remain in effect until 20...

Pfizer embarks on generics business in Japan.
November 30, 2009... Pfizer Japan will go aboard the generic pharmaceuticals business in Japan. The company's recently created Established Products Business Unit (EFBU) will be renamed Established Products Business Division on 1 Dec 2009. Pfizer Japan will improve...

Market for generics to expand to Yen 447.9 bn in 2011: Fuji Keizai.
November 30, 2009... The generics market will further grow at a rate of 24.1% to Yen 391.8 bn in 2009 and Yen 447.9 bn in 2011 from Yen 360.8 bn in 2008, according to the 2009 Generics Data Book compiled by Fuji Keizai. The market expanded by 8% in FY 2008,...

NDA for liraglutide, vildagliptin to be reviewed.
November 30, 2009... An NDA for liraglutide (proposed brand name: Victoza SC Injection), a glucagon-like peptide-1 (GLP-1) analogue from Novo Nordisk, will be reviewed by the CDFS' First Committee on Drugs at a meeting slated for 27 Nov 2009. If cleared, liraglutide...

ARB + calcium blocker combinations to be reviewed.
November 30, 2009... The CDFS' First Committee on Drugs will review applications for Novartis' Exforge Combination Tablet (valsartan + amlodipine) and Daiichi Sankyo's Rezaltas Combination Tablet (olmesartan + azelnidipine). Both products are fixed-dose combinations...

Evorolimus to be reviewed for renal cell cancer.
November 30, 2009... Two anticancer drugs, namely Novartis Pharma's Afinitor (everolimus) for renal cell cancer and Taiho Pharmaceutical's Abraxan for IV Drip Infusion (paclitaxel) for breast cancer, will be come under review by the CDFS's Second Committee on Drugs...

Chugai's Epogin applied for chemotherapy-induced anaemia.
November 30, 2009... Chugai Pharmaceutical filed on 19 Nov 2009 an approval application for Epogin Injection (recombinant epoetin beta), for the additional indication of chemotherapy-induced anaemia. According to a Japanese phase III study, patients who were treated...

Astellas applies for ASP8825 for RLS in Japan.
November 30, 2009... Astellas Pharma Inc submitted on 19 Nov 2009 a new drug application for ASP8825 (gabapentin enacarbil) extended-released tablets with restless legs syndrome (RLS) as indication. Acceptance of the NDA filing in Japan results in a $5 M milestone...

FDA warns against concurrent use of omeprazole and Plavix.
November 30, 2009... The FDA issued on 17 Nov 2009 a warning on the simultaneous administration of proton pump inhibitor (PPI) omeprazole and the antiplatelet drug Plavix (clopidogrel), saying that omeprazole lessens Plavix's anticoagulant effect. The safety...

Sep 2009 sales of ethical drugs up 6.2% driven by flu-related products: Crecon. [1 table in original article].
November 30, 2009... Sales of ethical and over-the-counter (OTC) drugs in Sept 2009 rose 6.2% and 6%, respectively, compared with the Sep 2008 level, according to a preliminary drug sales report released by Crecon Research and Consulting. Sales of OTC drugs were...

TAK-438 enters phase II for reflux oesophagitis: Takeda.
November 30, 2009... Takeda Pharmaceutical's TAK-438, a drug indicated for acid-related diseases, has entered into phase II clinical testing for reflux oesophagitis in Japan. Trial completion is expected in 1H 2011. TAK-438, a successor of Takepron (lansoprazole),...

Liraglutide prevents weight gain in Japanese patients.
November 30, 2009... Novo Nordisk Pharma presented on 6 Nov 2009 the results of two phase III trials validating the long-term clinical efficacy and weight-gain-preventing properties of liraglutide, its human glucagon-like peptide-1 analogue, in Japanese patients...

Taisho acquires BMS's OTC drugs business in Asia, Pacific.
November 30, 2009... Taisho Pharmaceutical successfully acquired on 30 Oct 2009 Bristol-Myers Squibb's OTC drugs trademarks for Yen 14.6. bn, and a 97.97% share in Bristol-Myers Squibb Indonesia (BMSI) for Yen 13.7 bn, or an aggregate of Yen 28.2 bn. Taisho will...

Sato Pharm launches switch OTC version of vidarabine.
November 30, 2009... Sato Pharmaceutical introduced on 16 Nov 2009 Arasena S, its OTC version of Mochida Pharmaceutical's Arasena-A Ointment 3% containing vidarabine, an anti-herpes agent, as the active ingredient. The drug has been classified as a Class 1 OTC drug...

Kobayashi Pharm: sales up 4.9% due to influenza pandemic: Apr-Sep 2009.
November 30, 2009... Sales in Kobayashi Pharmaceutical's mainstay household products business grew 4.9% to Yen 57,191 M in Apr-Sep 2009, mainly fuelled by favourable sales of new products and influenza-related products, such as masks. Sales of pharmaceuticals and...

Adverse reactions reported due to GSK's flu vaccine.
November 30, 2009... GlaxoSmithKline (GSK) has notified Canadian health authorities to shelve certain lot of GSK's adjuvanted H1N1 pandemic vaccine Arepanrix until investigations on the reported high incidence of serious allergic reactions (anaphylaxis) related to...

Rohto posts record-high sales driven by cosmetic business.
November 30, 2009... Rohto Pharmaceutical reported record-high sales, operating and ordinary profits, mainly driven by the robust sales of its cosmetic products including Hadalabo. Sales grew 1.7% to Yen 25,254, while operating profits increased 17.8% to Yen 5259 M,...

Xolair recommended in JGL2009.
November 30, 2009... The Asthma Prevention and Management Guidelines 2009, Japan (JGL2009) has recommended Novartis Pharma's anti-IgE antibody Xolair (omalizumab) as an additional option in Step 4 asthma therapy. JGL2009 has specified Xolair's efficacy against...

Rasilez's benefits for hypertension recognized by updated ESH GL: Novartis.
November 30, 2009... The updated European Society of Hypertension (EHS) guidelines acknowledged the efficacy of Novartis' direct rennin inhibitor (DRI) Rasilez (aliskiren) in lowering high blood pressure. Rasilez is effective when administered both as a monotherapy...

Zeria aims at 50% market share for Asacol: President Ibe.
November 30, 2009... Zeria Pharmaceutical is committed to capturing 50% of the market for the ulcerative colitis drug Asacol (mesalamine), according to company president Sachiaki Ibe. The company expects to commercialize the drug jointly with Kyowa Hakko Kirin in...

MSD launches prostaglandin eye drops without preservatives in the UK.
November 30, 2009... Merck Sharp & Dohme launched Saflutan eye drops without preservatives for the treatment of glaucoma in Great Britain. The product contains the new prostaglandin tafluprost and is indicated for the reduction of elevated inside pressure in the...

New drug for the treatment of dyslipidaemia available in the UK.
November 30, 2009... Merck Sharp & Dohme launched the new pharmaceutical Tredaptive for the treatment of dyslipidaemia in Great Britain. The drug contains nicotinic acid and the DP1-receptor antagonist laropiprant. Tredaptive has been approved for use in...

FDA approves new treatment for advanced kidney cancer.
November 30, 2009... The US Food and Drug Administration (FDA) approved the pharmaceutical Votrient (pazopanib) for kidney cancer manufactured by GlaxoSmithKline. The drug is administered orally and inhibits the new formation of blood vessels so that solid tumours...

New pharmaceutical for the treatment of psoriasis.
November 30, 2009... The US Food and Drug Administration (FDA) approved Stelara (ustekinumab), a biotechnology pharmaceuticals for adults who suffer from a medium-severe to severe form of psoriasis. Plaque-psoriasis is a disorder of the immune system which leads to...

New drug for the treatment of severe angiooedema.
November 30, 2009... The US Food and Drug Administration (FDA) approved Berinert, the first pharmaceuticals for the symptoms of a rare and potentially life-threatening hereditary disease called hereditary angiooedema (HAE). Berinert is manufactured by German company...

DSM presents high quality ingredients with maximum consumer appeal.
November 30, 2009... DSM is launching MaxiBright, a natural enzyme of whey decolourification and soy milk decolouring. It is also launching Panamore Spring, an alternative to CSL and SSL chemical emulsifiers.

Biopolymers from vegetal sources.
November 30, 2009... KitoZyme has developed technology to produce high-purity chitin-glucan and chitosan from exclusively, non-genetically modified plant sources. KiOnutrime-CG (vegetal chitin-glucan) and KiOnutrime-Cs (vegetal chitosan) will be used in food...

PL Thomas proudly introduces an exciting, new satiety ingredient.
November 30, 2009... PL Thomas is launching a new weight management ingredient which helps increase satiety and reduces feelings of hunger. This is currently in patent registration. PLT and Laila Nutra India are also launching an ingredient which acts directly on...

Cognis first company to achieve novel food approval for CLA in China.
November 30, 2009... Cognis Nutrition & Health has obtained Chinese approval for Tonalin CLA (conjugated linoleic acid) for use in functional foods and beverages.

Wacker and Dow Corning start to build second phase of pyrogenic silica plant in China.
November 30, 2009... Wacker Chemie and Dow Corning have begun the second phase of construction for a pyrogenic silica plant in Zhangjiagang, China. The project also includes a siloxane plant as part of an integrated silicone production site. The complex produces for...

The Hain Celestial Group announces joint venture with Hutchison China Meditech.
November 30, 2009... Hain Celestial has entered into a joint venture agreement with Hutchison China Meditech for the development of natural and organic consumer products in Asia.

Parlux announces an 8% increase in 2Q net sales.
November 30, 2009... Parlux Fragrances has reported estimated unaudited net sales of $56.5 M for its 2Q ended 30 Sep 2009 (+8% on the 2Q of 2008/2009).

Polydextrose: Tate & Lyle.
November 30, 2009... Anne Barry of the Tate & Lyle Innovation Centre at Villeneuve d'Asq, France gives an overview of the benefits of polydextrose as a source of soluble fibre for foods. The centre works with food manufacturers to create new formulations and...

Danish plant to fuel climate talks.
November 30, 2009... Biomass treatment company Inbicon has inaugurated a second-generation 1.5 M gallon/y ethanol facility in Kalundorg, Denmark to produce ethanol fuel for cars of VIP attendees of the Global Climate Summit in Copenhagen, Denmark to be held on 7-18...

Biopharma plant slated for Abu Dhabi.
November 30, 2009... Middle East investors are spending $150 M to build the Emirates Biotech Pharmaceutical Factory in Abu Dhabi, UAE. The company, created to produce biopharmaceuticals, will manufacture anticancer drugs, insulin, growth factors and vaccines that...

Soligenix receives grant.
November 30, 2009... The National Institute of Allergy and Infectious Diseases has awarded Soligenix a $9.4 M grant to finance an academic-industry consortium that develops vaccines that are stable even at high temperatures. The firm has made an option deal with the...

Thinking big, acting small: GSK banks on small science teams that act entrepreneurially.
November 30, 2009... GlaxoSmithKline has restructured its drug discovery activities to remove organizational hierarchy and give small research teams control over their projects in order to increase robustness while lessening the costs of the new-drug pipeline. In...

Cost-cutting contract: USW to vote on pact at Bridgestone plant.
November 30, 2009... Members of the United Steelworkers (USW) Local 1055 working at Bridgestone Americas Inc's La Vergne tyre facility in Tennessee, USA are slated to vote the week of 30 Nov 2009 on cost reduction initiatives that would guarantee the continued...

Taking its toll: impact of tariffs on Chinese-made tyres varies from firm to firm.
November 30, 2009... Private and import tyre label marketers in the USA are already feeling the effects of the US government's implementation of a 35% tariff on Chinese tyre imports, although the impact has differed largely from company to company depending on how...

Goodyear to close plant, cut 90 jobs.
November 30, 2009... Goodyear plans to shut down its Spartanburg, SC, USA retread materials unit by end-2009. The move will affect 90 employees, with the majority to be laid off. The Spartanburg facility manufactures retread materials for use in commercial and...

Struktol to distribute for Emerald.
November 30, 2009... Emerald Performance Materials LLC has name Struktol Co of America as the main sales distributor of its Good-Rite range of antioxidant products for thermoplastic applications in the NAFTA region. Under the agreement, the partners will also work...

GPX to sell solid tyre business to investor group.
November 30, 2009... A group of investors, known as MITL Acquisition Co LLC, has agreed to acquire GPX International Tire Corp's solid tyre business for $10 M. The purchase will include the MITL, ITL and Brawler brands, together will GPX's solid tyre factory in...

First of many: Ellsin breaks ground for pilot plant for tire recycling, plans 20-30 more.
November 30, 2009... Tyre recycling firm Ellsin Environmental Ltd recently started development of a 10,000 sq ft pilot unit in Sault Ste Marie, ON, Canada, with completion expected by May or Jun 2010. Cost of construction is estimated at between $5.5 M and $5.7 M....

North America bound: Nokian's eNTYRE is first all-season product for market.
November 30, 2009... Nokian Tyres Inc aims to bolster its position in the North American tyre market with eNTYRE, its first all-season tyre. The potential market for eNTYRE is estimated at around 50 M units. Until now, Nokian has marketed only winter and summer...

Michelin, Bridgestone launch new projects in India.
November 30, 2009... Michelin plans to invest $870 M for the construction of a truck tyre facility in southern India in the next two to three years. The firm already acquired 290 acres of land in Tiravallur nearby Chennai, where the new plant will be built. The...

Merquinsa introduces eco-thermoplastic polyurethane.
November 30, 2009... Merquinsa North America Inc has unveiled Pearlthane ECO thermoplastic polyurethane (TPU), featuring new Bio TPU grades with up to 60% renewable content. The materials can be used as substitute for petroleum-based TPUs or thermoplastic elastomers...

New York to be scrap tyre free in 2010.
November 30, 2009... The New York Department of Environmental Conservation announced that the US state is on course to clear out its remaining 7.5 M scrap tyres by end-2010, after cleaning up over 26.5 M scrap tyres since 2004. Twelve of the 17 major tyre dumps in...

FDA approves vaccine against papilloma virus.
November 30, 2009... The US Food and Drug Administration (FDA) approved the vaccine Gardasil from Merck for the application against genital warts in boys and men aged between 9-26 years. The vaccine protects against several strains of the human papilloma virus (HPV)...

Mitsubishi Corp provided solar power generation system to non-electrified villages in Eithiopia.
November 30, 2009... On the 29 Nov 2009 Mitsubishi Corp, in collaboration with Ministry of Agriculture and Rural Development (MOARD) of Ethiopia, conducted the inaugural ceremony of the Solar PV Power Generation System installed at Maki Village of Oromia Regional...

New approvals of pharmaceuticals by the FDA.
November 30, 2009... The US Food and Drug Administration (FDA) approved following pharmaceuticals during 25 Sep-19 Oct 2009: Stelara (ustekinumab) for psoriasis from Centocor Ortho Biotech Inc; Jenloga (clonidin hydrochloride) for hypertension from Addrenex; Welchol...

Pfizer's plans for the R&D segment.
November 30, 2009... The large research and development (R&D) division of Pfizer grew in size after the acquisition of the pharmaceuticals company Wyeth. Pfizer plans to decentralize its R&D to more than 18 different units. However the different R&D...

Nizhnekamsk plans world-scale petchems complex.
November 30, 2009... Nizhnekamskneftekhim, the Russian producer of petrochemicals and synthetic rubber, is planning to build complex centred on a 1 M tonne/y ethylene unit at Nizhnekamsk. Successful completion of a feasibility study in 2010 could enable construction...

Idemitsu to commercialize PAO technology at new plant in Japan.
November 30, 2009... In 2H 2010, Tokyo-based Idemitsu Kosan will decide whether to build a facility for poly-alpha-olefins (PAQ) based on metallocene catalysts technology. The facility will probably be located at Chiba, where the company operates a 600,000 tonne/y...

Perstorp to build aliphatic isocyanates unit in China.
November 30, 2009... Perstorp is planning to construct a Chinese facility for aliphatic polyisocyanates. The 12,000 tonne/y facility, startup of which is scheduled for 2012, will enable the company to meet rising demand in both China and elsewhere in Asia. Perstorp...

Chemtura to expand antioxidant capacity in Saudi Arabia.
November 30, 2009... Gulf Stabilizer Industries (GSI), a joint venture between Chemtura and the Al-Zamil Group, is to increase its capacity for antioxidants at Al Jubail, Saudi Arabia, from 4000 tonne/y to 21,000 tonne/y. Engineering work is in progress and the...

Mitsui launches public share offering to fund Chinese plants.
November 30, 2009... A public share offering by Mitsui Chemicals, which should raise Yen 64.3 bn, will help the company to finance an expansion of its Chinese operations. Some of the funds will provide working capital for Foshan Mitsui Chemicals Polyurethanes Co, an...

Olin boosts bleach shipments by rail.
November 30, 2009... Proprietary rail-car technology developed by Olin now enables the firm to deliver high-quality bleach cost effectively for distances of over 1000 miles. Olin's fleet of 100 specifically designed rail cars will be increased to around 300 by...

Distribution: charting path to recovery.
November 30, 2009... The recovery of the chemical distribution sector following the global recession is elucidated. Although sales by Ashland Distribution dropped 33% to $771 M in 4Q fiscal 2009 they were up 10% compared with the previous quarter. A possible initial...

Karib Kemi initiates call-back campaign.
November 30, 2009... British company Karib Kemi Pharm Ltd in Croydon launched a call-back campaign for more than 100 batches of pharmaceuticals due to insufficient dispatch conditions on the sea transport from its contract manufacturer oversees. The call-back...

Medco to provide pharmacy homecare service.
November 30, 2009... Medco Health Solutions (UK), a new organisation which originates from Ireland and the US, plans to offer a homecare service for pharmacies. The company will offer services to the British National Health Service (NHS) such as the distribution of...

FDA accelerates approval proceedings for new heart drug.
November 30, 2009... The US Food and Drug Administration (FDA) is accelerating the approval proceedings for relaxin, a potential pharmaceuticals for acute cardiac insufficiency. US biotechnology company Corthera in San Mateo, CA is currently testing relaxin in a...

Kollodis BioSciences, Inc enters into agreement to develop cosmetic glue adhesives.
November 30, 2009... Kollodis BioSciences has signed an agreement with Lifeace Co. Ltd for the development and marketing of Kollodis' recombinant mussel adhesive protein compositions. This covers their use for cosmetic glues and related adhesive applications.

Shiseido to commence sales in the Republic of Azerbaijan.
November 30, 2009... Shiseido is to begin selling its products in Azerbaijan from Dec 2009.

Shiseido inks joint-venture agreement with Gerolymatos Cosmetics SA in Greece.
November 30, 2009... Shiseido International Europe SA has entered into a joint venture with Gerolymatos Cosmetics. Gerolymatos Cosmetics is a subsidiary Alapis which imports and sells cosmetics on the Greek market.

Drug R&D heats up in Beijing.
November 30, 2009... New developments in Beijing is increasing the Chinese city's popularity as a research hub. US contract drug R&D company Pharmaceutical Product Development will acquire BioDuro, a drug discovery services firm. BioDuro has 660 workers in...

Clariant to cut 570 jobs.
November 30, 2009... Clariant, a specialty chemical supplier, will eliminate 570 jobs in line with the next stage of its initiative to optimize production. The newly announced layoff and two previous rounds bring the total of job cuts to about 3220. The firm is...

Carbon nanotubes coat ship hull.
November 30, 2009... Bayer claims that its carbon nanotubes harden and smoothen a ship-hull coating that it glides through the water, reducing both fuel usage and flow resistance. The two-part epoxy mastic resin coatings containing nanotubes are being tested on...

BASF to shutter paper coatings site.
November 30, 2009... BASF plans to cease the manufacture of styrene-butadiene latex (SBL) paper coating binders at its facilities in Kaipiainen, Finland; Ribecourt, France and Guturribay, Spain by mid-2010 due to overcapacity. The closures make up 40% of the firm's...